RxDoctor Payments Data

Glenn Curtis, APRN

Family · Searcy, ARNPI 1609949486

Payments from drug & device makers

$191in general payments, 2019–2025

Across 13 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$69
  • AstraZeneca$29
  • Novo Nordisk$27
  • Amgen$18
  • Boehringer Ingelheim$18
  • Biohaven Pharmaceuticals, Inc.$15
  • plus $14 from 2 others

What the payments were for

  • Food & beverage$18999%
  • Education$21%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$191 in reported general payments places this provider in the 35th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$58,839
Medicare patients
273
Services billed
1,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$101,905
MounjaroTirzepatide55$69,267
JardianceEmpagliflozin102$68,675
Tresiba Flextouch U-200Insulin Degludec108$66,057
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$41,445
Synjardy XrEmpagliflozin/Metformin Hcl51$37,486
XareltoRivaroxaban48$30,987
EliquisApixaban51$29,910
TrulicityDulaglutide12$17,252
LinzessLinaclotide20$15,606
SynjardyEmpagliflozin/Metformin Hcl24$15,393
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,672
Praluent PenAlirocumab17$8,647
JanuviaSitagliptin Phosphate12$6,918
Repatha SureclickEvolocumab12$6,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$18$121,555177 claims
Novo NordiskOzempic$27$101,90599 claims
AstraZenecaBreztri Aerosphere$29$9,67215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,103 family providers in Arkansas.

Other family in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →